US FDA Grant Fast-Track Glioblastoma Treatments
Unfortunately, glioblastoma is an aggressive brain tumor that still remains difficult to treat.
To this day, there is still an unmet need for treatment, with only 8.7% of patients surviving for up to two years, according to Tactical Therapeutics.
However, it appears some companies are making sizable progress in helping those suffering from glioblastoma.
For example, Plus Therapeutics’ stock was higher after receiving Fast Track status from the US FDA for its potential treatment.
Kazia Therapeutics also just received FDA Fast Track status with its paxalisib.
Companies such as WPD Pharmaceuticals just received further funding for its drug candidate targeting glioblastoma, as well.
In all, some of the top companies to keep an eye on with such developments include
WPD Pharmaceuticals Inc. (CSE:WBIO),
Kazia Therapeutics Ltd. (NASDAQ:KZIA),
Plus Therapeutics Inc. (NASDAQ:PSTV),
Novocure Ltd. (NASDAQ:NVCR), and
AstraZeneca PLC (NYSE:AZN).